By contrast, CX showed protective effects against ER− breast cancer, although its effect showed no statistical significance for ER−/PR+ and ER−/PR− breast cancers (sES, 0.945; 95% CI, 0.896 to 0.997). This evidence concerns the gene PGR and breast cancer.